NexMed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product

April 2007
Equities;Apr2007, Vol. 55 Issue 2, p124
The article reports on the start of patient dosing in the Phase 3 clinical trials for NM100060 anti-fungal treatment of Novartis according to NexMed Inc. which signed a licensing agreement with the pharmaceutical firm. It states that two pivotal, randomized, double-blind and placebo-controlled studies are contained in the program which aimed to assess the efficacy, safety and tolerability of the treatment in patients with mild toenail onychomycosis.


Related Articles

  • Financings Roundup.  // BioWorld Today;5/15/2008, Vol. 19 Issue 95, p3 

    The article reports on a binding commitment entered by NexMed Inc. of East Windsor, New Jersey with one of its largest shareholders for a line of credit. The company intends to use the money to bridge the anticipated payments from partner Novartis AG, which licensed rights to NM100060 of NexMed....

  • Senesco Initiates Dosing in Phase 1b/2a Clinical Study of SNS01-T.  // Biomedical Market Newsletter;11/7/2011, Vol. 21, p189 

    The article reports on the start of patient dosing by Senesco Technologies Inc. for its Phase 1b/2a clinical study of SNS01-T at the Mayo Clinic in Rochester, Minnesota in 2011. It says that the study aimed to assess the safety and tolerability of SNS01-T. It notes that dosing is applied twice a...

  • NexMed Shares Fall Hard as Novartis Nixes NDA. Hollingsworth, Catherine // BioWorld Today;8/28/2008, Vol. 19 Issue 168, p1 

    The article reports on a decline in the value of NexMed's shares by 81.6% after its partner, Novartis AG, decided not to file for a new drug application for a topical nail fungus product that uses NexMed's drug delivery technology. Such decision by Novartis was attributed to a negative Phase III...

  • Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Two Different Escalating Strategies for Pregabalin and Oxycodone Combination Therapy for Neuropathic Pain in Cancer Patients. Garassino, Marina Chiara; Piva, Sheila; La Verde, Nicla; Spagnoletti, Ilaria; Iorno, Vittorio; Carbone, Claudia; Febbraro, Antonio; Bianchi, Anna; Bramati, Annalisa; Moretti, Anna; Ganzinelli, Monica; Marabese, Mirko; Gentili, Marta; Torri, Valter; Farina, Gabriella // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    Purpose: Neuropathic pain is commonly associated with cancer. Current treatments include combination opioid and adjuvant therapies, but no guidelines are available for dose escalation strategies. This phase II study compared the efficacy and tolerability of two dose escalation strategies for...

  • Deals roundup.  // Medical Device Daily;7/9/2009, Vol. 13 Issue 130, p3 

    The article reports on the mutual decision of NexMed and Novartis to terminate their licensing agreement for NM100060, a topically-applied treatment for nail fungus. The licensing agreement was completed by the companies in September 2008. According to NexMed, the results of two Phase III...

  • Infectious Diseases News Round-Up.  // PharmaWatch: Monthly Review;Aug2009, Vol. 8 Issue 8, p21 

    The article offers world news briefs related to the pharmaceutical industry. Baxter International Inc. is developing an A/H1N1 vaccine using its Vero cell culture technology to respond the outbreak of H1N1 influenza. Novartis AG has received requests from over 30 governments for the delivery of...

  • NexMed's U.S. patent triggers a milestone payment from Novartis.  // Medical Device Daily;10/29/2008, Vol. 12 Issue 211, p8 

    The article reports that the U.S. Patent & Trademark Office has issued a notice of allowance for NexMed's U.S. patent application titled, "Antifungal Nail Coat and Method of Use." The patent covers NM100060, a topical application of terbinafine formulated with NexACT for the treatment of...

  • The impact of baseline faecal egg counts on the efficacy of single-dose albendazole against Trichuris trichiura Levecke, B.; Mekonnen, Z.; Albonico, M.; Vercruysse, J. // Transactions of the Royal Society of Tropical Medicine & Hygiene;Feb2012, Vol. 106 Issue 2, p128 

    Abstract: There is considerable variation in the efficacy of single-dose albendazole (400mg) against Trichuris trichiura across human trials. Factors contributing to this variation have not yet been identified. We assessed the impact of mean baseline faecal egg counts (FEC) on the efficacy of...

  • A comparative trial of a new antidepressant, fluoxetine. Levine, S.; Deo, A.; Mahadevan, K.; Deo, R // British Journal of Psychiatry;May87, Vol. 150, p653 

    This clinical trial of a new antidepressant, fluoxetine, shows it to be as effective as a standard tricyclic drug, imipramine. It is effective as a single daily dose and is free of any significant side-effects. It is less sedative and appears to cause fewer problems of weight increase. The three...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics